GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ENCell Co Ltd (XKRX:456070) » Definitions » Capex-to-Operating-Income

ENCell Co (XKRX:456070) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is ENCell Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

ENCell Co's Capital Expenditure for the three months ended in Mar. 2025 was ₩-584.27 Mil. Its Operating Income for the three months ended in Mar. 2025 was ₩-4,766.70 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


ENCell Co Capex-to-Operating-Income Historical Data

The historical data trend for ENCell Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENCell Co Capex-to-Operating-Income Chart

ENCell Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
- - - - -

ENCell Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ENCell Co's Capex-to-Operating-Income

For the Biotechnology subindustry, ENCell Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENCell Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ENCell Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where ENCell Co's Capex-to-Operating-Income falls into.


;
;

ENCell Co Capex-to-Operating-Income Calculation

ENCell Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-641.338) / -15683.11
=N/A

ENCell Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-584.267) / -4766.699
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ENCell Co  (XKRX:456070) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


ENCell Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of ENCell Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


ENCell Co Business Description

Traded in Other Exchanges
N/A
Address
701 Yeongdong-daero, 11th floor, Gangnam-gu, Seoul, KOR
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.

ENCell Co Headlines

No Headlines